HRP20200836T1 - Liječenje bolesti povezanih s imunitetom i upalnih bolesti - Google Patents
Liječenje bolesti povezanih s imunitetom i upalnih bolesti Download PDFInfo
- Publication number
- HRP20200836T1 HRP20200836T1 HRP20200836TT HRP20200836T HRP20200836T1 HR P20200836 T1 HRP20200836 T1 HR P20200836T1 HR P20200836T T HRP20200836T T HR P20200836TT HR P20200836 T HRP20200836 T HR P20200836T HR P20200836 T1 HRP20200836 T1 HR P20200836T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- disease
- scleroderma
- lupus erythematosus
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 206010039710 Scleroderma Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims 3
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 claims 3
- 206010011674 Cutaneous sarcoidosis Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 201000003088 Limited Scleroderma Diseases 0.000 claims 1
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (14)
1. Spoj za uporabu u postupku liječenja, sprječavanja ili upravljanja imunološkom bolešću ili upalnom bolešću, naznačen time što postupak sadrži primjenu, pacijentu kojemu je potreban, djelotvorne količine navedenog spoja, i pri čemu spoj je spoj formule I
[image]
ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, stereoizomer, tautomer ili racemična smjesa, i gdje je bolest lupus, skleroderma, lupus pernio, sarkoidoza, Sjögrenov sindrom, ANCA-izazvan vaskulitis, antifosfolipidni sindrom ili miastenija gravis.
2. Spoj za uporabu prema zahtjevu 1, naznačen time što je bolest sistemski eritematozni lupus, kožni eritematozni lupus, skleroderma, lupus pernio, sarkoidoza ili Sjögrenov sindrom.
3. Spoj za uporabu prema zahtjevu 2, naznačen time što je bolest sistemski eritematozni lupus.
4. Spoj za uporabu prema zahtjevu 3, naznačen time što je sistemski eritematozni lupus teški sistemski eritematozni lupus.
5. Spoj za uporabu prema zahtjevu 2, naznačen time što je bolest kožni eritematozni lupus.
6. Spoj za uporabu prema zahtjevu 2, naznačen time što je bolest skleroderma.
7. Spoj za uporabu prema zahtjevu 6, naznačen time što je skleroderma lokalizirana, sistemska, ograničena ili difuzna skleroderma.
8. Spoj za uporabu prema zahtjevu 7, naznačen time što sistemska skleroderma sadrži CREST sindrom.
9. Spoj za uporabu prema zahtjevu 2, naznačen time što je bolest Sjögrenov sindrom.
10. Spoj za uporabu prema bilo kojem od zahtjeva 1-9, naznačen time što je spoj (S)-3-[4- (4-morfolin-4-ilmetilbenziloksi)-1-okso-1,3-dihidro-izoindo-2-il]piperidin-2,6-dion formule IA
[image]
ili njegova farmaceutski prihvatljiva sol, solvat, hidrat ili tautomer.
11. Spoj za uporabu prema zahtjevu 10, naznačen time što je spoj (S)-3-[4-(4-morfolin-4-ilmetilbenziloksi)-l-okso-l,3-dihidro-izoindo-2-il]piperidin-2,6-dion.
12. Spoj za uporabu prema zahtjevu 10, naznačen time što je spoj (S)-3-[4-(4-morfolin-4-ilmetilbenziloksi)-l-okso-l,3-dihidro-izoindo-2-il]piperidin-2,6-dionski hidroklorid.
13. Spoj za uporabu prema bilo kojem od zahtjeva 1-12, naznačen time što postupak nadalje sadrži primjenu drugog aktivnog sredstva, koje je protuupalni ili imunomodulatorni spoj.
14. Spoj za uporabu prema bilo kojem od zahtjeva 1-13, naznačen time što efektivna količina navedenog spoja iznosi od oko 0.005 mg / kg do oko 10 mg / kg pacijentove tjelesne težine.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261681491P | 2012-08-09 | 2012-08-09 | |
US201261722718P | 2012-11-05 | 2012-11-05 | |
PCT/US2013/054051 WO2014025958A2 (en) | 2012-08-09 | 2013-08-08 | Treatment of immune-related and inflammatory diseases |
EP13752753.7A EP2882441B1 (en) | 2012-08-09 | 2013-08-08 | Treatment of immune-related and inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200836T1 true HRP20200836T1 (hr) | 2020-08-07 |
Family
ID=49029213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200836TT HRP20200836T1 (hr) | 2012-08-09 | 2020-05-22 | Liječenje bolesti povezanih s imunitetom i upalnih bolesti |
Country Status (30)
Country | Link |
---|---|
US (2) | US10919883B2 (hr) |
EP (2) | EP2882441B1 (hr) |
JP (2) | JP6250671B2 (hr) |
KR (3) | KR102266509B1 (hr) |
CN (4) | CN104703605A (hr) |
AU (1) | AU2013299625B2 (hr) |
BR (1) | BR112015002272A2 (hr) |
CA (2) | CA3092279C (hr) |
CY (1) | CY1123106T1 (hr) |
DK (1) | DK2882441T3 (hr) |
EA (1) | EA029085B1 (hr) |
ES (1) | ES2800026T3 (hr) |
HK (1) | HK1211474A1 (hr) |
HR (1) | HRP20200836T1 (hr) |
HU (1) | HUE049569T2 (hr) |
IL (1) | IL237070B (hr) |
LT (1) | LT2882441T (hr) |
MX (1) | MX2015001686A (hr) |
NI (1) | NI201500013A (hr) |
NZ (2) | NZ628077A (hr) |
PH (1) | PH12015500276A1 (hr) |
PL (1) | PL2882441T3 (hr) |
PT (1) | PT2882441T (hr) |
RS (1) | RS60416B1 (hr) |
SG (1) | SG11201500983RA (hr) |
SI (1) | SI2882441T1 (hr) |
TW (1) | TWI641371B (hr) |
UA (1) | UA116992C2 (hr) |
WO (1) | WO2014025958A2 (hr) |
ZA (1) | ZA201500466B (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2567753C2 (ru) | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
AU2014236597A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives |
WO2015179279A1 (en) * | 2014-05-19 | 2015-11-26 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US10245266B2 (en) * | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
LT3496739T (lt) | 2016-07-15 | 2021-05-25 | Acceleron Pharma Inc. | Kompozicijos ir būdai, skirti plaučių hipertenzijai gydyti |
US10969381B2 (en) * | 2018-05-23 | 2021-04-06 | Celgene Corporation | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile |
MX2021003842A (es) | 2018-10-01 | 2021-05-27 | Celgene Corp | Terapia combinada para el tratamiento del cancer. |
US11255850B2 (en) | 2019-03-28 | 2022-02-22 | Alentic Microscience Inc. | Bead-based analysis of a sample |
US10684278B1 (en) | 2019-03-28 | 2020-06-16 | Alentic Microscience Inc. | Bead-based analysis of a sample |
US11719700B2 (en) | 2019-03-28 | 2023-08-08 | Alentic Microscience Inc. | Upconversion for microscopy |
US11609233B2 (en) | 2019-03-28 | 2023-03-21 | Alentic Microscience Inc. | Indicator-based analysis of a sample |
WO2021108303A1 (en) * | 2019-11-25 | 2021-06-03 | PHPrecisionMed, LLC | Pharmaceutical compositions for the treatment of pulmonary hypertension |
WO2023097111A2 (en) * | 2021-11-29 | 2023-06-01 | Riptide Bioscience, Inc. | Methods and compositions for treating calcinosis associated conditions |
WO2024064646A1 (en) | 2022-09-20 | 2024-03-28 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
AU7871298A (en) | 1996-12-20 | 1998-07-17 | Takeda Chemical Industries Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
EP1357120A1 (en) | 1998-03-16 | 2003-10-29 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
DE60236861D1 (de) | 2001-04-26 | 2010-08-12 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
GB0120441D0 (en) | 2001-08-22 | 2001-10-17 | Novartis Forschungsstiftung | Model of autoimmune disease and methods for identifying anti autoimmune disease disorders |
US7173032B2 (en) | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
WO2006055689A2 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
EP2032716A4 (en) * | 2006-05-12 | 2010-03-17 | Univ Miami | BIOMARKERS FOR THE DETECTION AND DIAGNOSIS OF SPINOCELLULAR MALIPHELL EPIDELIOMA OF THE HEAD AND NECK |
US20080045485A1 (en) | 2006-08-17 | 2008-02-21 | Peter Muir | Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture |
WO2008076356A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
WO2008115516A2 (en) | 2007-03-20 | 2008-09-25 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
AU2008234374B2 (en) | 2007-03-30 | 2013-05-23 | Chu Sainte Justine | Method of determining risk of scoliosis |
JP5442185B2 (ja) * | 2007-04-24 | 2014-03-12 | 日本メナード化粧品株式会社 | 感作性物質評価方法 |
CA2720184C (en) * | 2008-03-31 | 2017-07-18 | Boston Medical Center Corporation | Predictive marker for topoisomerase i inhibitors |
WO2009126310A2 (en) | 2008-04-10 | 2009-10-15 | Massachusetts Institute Of Technology | Methods for identification and use of agents targeting cancer stem cells |
WO2011109440A1 (en) * | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as Bcl-2 selective apoptosis inducers for the treatment of cancer and immune diseases |
WO2010121231A1 (en) | 2009-04-18 | 2010-10-21 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
RU2567753C2 (ru) * | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения |
EP2606353A4 (en) | 2010-08-18 | 2014-10-15 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASE |
WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
AU2012271516A1 (en) * | 2011-06-16 | 2014-01-23 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
-
2013
- 2013-08-08 WO PCT/US2013/054051 patent/WO2014025958A2/en active Application Filing
- 2013-08-08 PL PL13752753T patent/PL2882441T3/pl unknown
- 2013-08-08 CN CN201380052686.2A patent/CN104703605A/zh active Pending
- 2013-08-08 CN CN202210426141.4A patent/CN115068484A/zh active Pending
- 2013-08-08 PT PT137527537T patent/PT2882441T/pt unknown
- 2013-08-08 EP EP13752753.7A patent/EP2882441B1/en active Active
- 2013-08-08 EP EP20170356.8A patent/EP3741372A1/en active Pending
- 2013-08-08 EA EA201590342A patent/EA029085B1/ru not_active IP Right Cessation
- 2013-08-08 RS RS20200718A patent/RS60416B1/sr unknown
- 2013-08-08 KR KR1020207014533A patent/KR102266509B1/ko active IP Right Grant
- 2013-08-08 CN CN201810897406.2A patent/CN108938642A/zh active Pending
- 2013-08-08 CA CA3092279A patent/CA3092279C/en active Active
- 2013-08-08 HU HUE13752753A patent/HUE049569T2/hu unknown
- 2013-08-08 DK DK13752753.7T patent/DK2882441T3/da active
- 2013-08-08 KR KR1020217018110A patent/KR20210073616A/ko active IP Right Grant
- 2013-08-08 NZ NZ628077A patent/NZ628077A/en unknown
- 2013-08-08 MX MX2015001686A patent/MX2015001686A/es active IP Right Grant
- 2013-08-08 ES ES13752753T patent/ES2800026T3/es active Active
- 2013-08-08 CN CN202210438882.4A patent/CN114939119A/zh active Pending
- 2013-08-08 TW TW102128577A patent/TWI641371B/zh active
- 2013-08-08 JP JP2015526688A patent/JP6250671B2/ja active Active
- 2013-08-08 SG SG11201500983RA patent/SG11201500983RA/en unknown
- 2013-08-08 LT LTEP13752753.7T patent/LT2882441T/lt unknown
- 2013-08-08 KR KR1020157005985A patent/KR102118559B1/ko active IP Right Grant
- 2013-08-08 US US13/962,786 patent/US10919883B2/en active Active
- 2013-08-08 AU AU2013299625A patent/AU2013299625B2/en active Active
- 2013-08-08 NZ NZ727295A patent/NZ727295A/en unknown
- 2013-08-08 CA CA2881113A patent/CA2881113C/en active Active
- 2013-08-08 UA UAA201501972A patent/UA116992C2/uk unknown
- 2013-08-08 SI SI201331725T patent/SI2882441T1/sl unknown
- 2013-08-08 BR BR112015002272A patent/BR112015002272A2/pt not_active Application Discontinuation
-
2015
- 2015-01-22 ZA ZA2015/00466A patent/ZA201500466B/en unknown
- 2015-02-02 IL IL237070A patent/IL237070B/en active IP Right Grant
- 2015-02-06 NI NI201500013A patent/NI201500013A/es unknown
- 2015-02-09 PH PH12015500276A patent/PH12015500276A1/en unknown
- 2015-12-14 HK HK15112280.7A patent/HK1211474A1/xx unknown
-
2017
- 2017-11-22 JP JP2017224295A patent/JP6595565B2/ja active Active
-
2020
- 2020-05-22 HR HRP20200836TT patent/HRP20200836T1/hr unknown
- 2020-06-19 CY CY20201100566T patent/CY1123106T1/el unknown
- 2020-11-23 US US17/102,237 patent/US20210340132A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200836T1 (hr) | Liječenje bolesti povezanih s imunitetom i upalnih bolesti | |
HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
JP2016528301A5 (hr) | ||
RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
JP2013510124A5 (hr) | ||
JP2014521735A5 (hr) | ||
RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
JP2015509102A5 (hr) | ||
TR201900199T4 (tr) | Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler. | |
JP2014526492A5 (hr) | ||
RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
JP2011507896A5 (hr) | ||
RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
BRPI0921097A2 (pt) | composto derivado de pirazol-3 carboxamida com atividade de antagonista de receptor 5-ht2b, agente preventivo ou terapêutico, composição farmacêutica e uso do composto ou seu sal farmaceuticamente aceitável e método ou prevenção ou tratamento. | |
RU2015140669A (ru) | Пиридинилпиразолохинолиновые соединения | |
PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
NZ608375A (en) | Pharmaceutical combination of an mtor catalytic inhibitor and an allosteric mtor inhibitor | |
HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
HRP20201152T1 (hr) | Kondenzirani benzazepin za liječenje mucanja | |
BR112019002513A2 (pt) | uso e dosagem de agentes terapêuticos para endometriose |